I have been “gone fishing [1]” for the last few days so most of the week’s developments were in a catch-all post that ranged from Sanofi’s further branching out into generics to a Dalhousie study on global fisheries management [2].
There were a couple of big catches this week:
- Venture-captialists seem to have reeled in some new funds [3] — the bills in Congress to reauthorize the SBIR (Small Business Innovation Research) program allow companies backed by VCs to participate.
- And Ogilvy Renault (my home-away-from-home) landed the Golden Law Award as Canada’s best law firm for the second year running [4].
And there are a couple of fishing expeditions still in progress:
- Dr. Reddy’s, the generics maker, is fishing for access to Celgene’s anti-cancer drug Revlimid to use in producing a generic version [5]; but so far the tight controls on Revlimid distribution are leaving them high and dry.
- And BIO and PhRMA are angling for a decision from the U.S. Supreme Court that would limit the number of whistleblower suits that could be brought [6] (those FCA claims are a major source of health care fraud litigation).
See what else the week spawned at the Cross-Border Biotech Blog [7].